Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, M. [1 ]
Vogelzang, N. J. [2 ]
Sartor, O. [3 ]
Armour, A. [4 ]
Groaning, M. [5 ]
Messmann, R. [6 ]
Robarts, A. [7 ]
Petrylak, D. P. [8 ]
Tolcher, A. [9 ]
Gordon, M. S. [10 ]
Babiker, H. [11 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA
[3] Tulane Univ, Oncol, New Orleans, LA 70118 USA
[4] Endocyte Inc, Med, Indianapolis, IN USA
[5] Endocyte, Clin, Indianapolis, IN USA
[6] Endocyte, Med Oncol, W Lafayette, IN USA
[7] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[8] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[9] START, Med Oncol, San Antonio, TX USA
[10] HonorHlth Res Inst, Med Oncol, Scottsdale, AZ USA
[11] Univ Arizona, Ctr Comprehens Canc, Med Oncol, Tucson, AZ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
793PD
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE II TRIAL OF CIRCULATING CYTOKINES AS MARKERS OF DOCETAXEL RESISTANCE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (mCRPC)
    Mahon, Kate
    Lin, H-M
    Spielman, C.
    Lee-Ng, M.
    Gurney, H.
    Mallesara, G.
    Stockler, M.
    Briscoe, K.
    Marx, G.
    Breit, S. N.
    Brown, D.
    Horvath, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 37 - 37
  • [22] OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    Corman, J.
    Dawson, N.
    Hall, S.
    Nabhan, C.
    Ferrari, A.
    Armstrong, A. J.
    Murdock, M. I.
    Stewart, F.
    Sheikh, N.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2012, 23 : 311 - 311
  • [23] A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Fong, Lawrence
    Morris, Michael
    Armstrong, Andrew
    Petrylak, Daniel
    Vaishampayan, Ulka
    Alva, Ajjai
    Hoffman-Censits, Jean
    Sarkar, Indrani
    Carroll, Susheela
    Schiff, Christina
    Sartor, Oliver
    CANCER RESEARCH, 2017, 77
  • [24] Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Dwabe, Sami
    Yazdanpanah, Omid
    Warnecke, Brian
    Benjamin, David Joseph
    Rezazadeh, Arash
    Mar, Nataliya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
    Petrylak, D.
    Kantoff, P.
    Mega, A.
    Stephenson, J.
    Vogelzang, N.
    Fleming, M.
    Blattman, S.
    Stambler, N.
    D'Ambrosio, P.
    Israel, R. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 75 - 75
  • [26] Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.
    Sandhu, Shahneen Kaur
    Violet, John A.
    Ferdinandus, Justin
    Thang, Sue-Ping
    Iravani, Amir
    Guo, Christina
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Timothy J.
    Beaulieu, Alexis
    Murphy, Declan G.
    Mooi, Jennifer
    Tran, Ben
    Toner, Guy C.
    Williams, Scott
    Hicks, Rodney J.
    Hofman, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
    Crumbaker, Megan
    Joshua, Anthony M.
    Epstein, Richard
    Emmett, Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    William R. Schelman
    Glenn Liu
    George Wilding
    Thomas Morris
    De Phung
    Robert Dreicer
    Investigational New Drugs, 2011, 29 : 118 - 125
12345